CEO: Vicente J. Anido

Sector: Health Technology

Exchange: NASDAQ

Country: US

Description: Aerie Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye. Its products include Rhopressa, Roclatan, AR-13503, and AR-1105. The company was founded by David L. Epstein, Casey C. Kopczynski, Thomas J. van Haarlem, and Eric J. Toone on June 22, 2005 and is headquartered in Durham, NC.


Key numbers

Market Capitalization:591198024
Shares Outstanding: 46514400
Float: 43904431
Next Earning Date:2020-11-10
TTm EPS: -4.4181
TTm Dividend Rate:
200 days moving average:17.12
50 days moving average: 13.63
One day percent Change: -1.93



2018-03-31, 2018-06-30, 2018-09-30, 2018-12-31,
2018-03-31, 2018-06-30, 2018-09-30, 2018-12-31,
2015-12-31, 2016-12-31, 2017-12-31, 2018-12-31,
2015-12-31, 2016-12-31, 2017-12-31, 2018-12-31,